Nutriband Inc. CEO Gareth Sheridan has published a letter to shareholders outlining the company's 2025 achievements and 2026 outlook. The update emphasized Nutriband's focus on shareholder value through disciplined capital management, including a 25% preferred stock dividend issued in 2025, and progress toward reducing share price volatility with the expiration of IPO-era warrants in October 2026. Significant advances were reported for the company's lead product, AVERSA™ Fentanyl, an abuse-deterrent opioid transdermal patch under development.
During 2025, Nutriband strengthened its intellectual property portfolio with new U.S. patent issuances, completed commercial manufacturing scale-up, and received FDA feedback through a Type C meeting to support its regulatory pathway. The company's AVERSA™ technology is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential when incorporated into transdermal patches. Additional 2025 milestones included the company's inclusion in four Russell indexes and strategic transactions intended to support long-term growth.
Nutriband continues advancing AVERSA™ Fentanyl toward commercialization as part of its portfolio of transdermal pharmaceutical products. The company's corporate website is available at https://www.nutriband.com for additional information about its development programs. The shareholder letter provides investors with insight into Nutriband's regulatory progress and financial strategy as the company moves closer to bringing its abuse-deterrent technology to market.
The development of AVERSA™ Fentanyl addresses concerns about opioid abuse while maintaining therapeutic benefits for patients requiring pain management through transdermal delivery systems. Nutriband's approach to shareholder communication through detailed updates reflects its commitment to transparency during the product development phase. The company's progress in 2025 positions it for continued advancement in 2026 as it works toward commercializing its proprietary abuse-deterrent technology platform.
